CD4 and neoplasm: To explore which immune populations mediate tumor rejection, we injected immunodepleting antibodies against either CD4+ and CD8+ T cells or NK cells into C57BL/6 mice bearing either T cell–inflamed EV or Mgat5-KO tumor cells (2838c3).